Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis-Reference-Cited by-同舟云学术

Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis

Published:2016-03-02 Issue:5 Volume:95 Page:695-706
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Adams Hugo J. A.,Kwee Thomas C.

Funder

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2619-9.pdf

Reference39 articles.

1. Cheson BD (2012) Hodgkin lymphoma: protecting the victims of our success. J Clin Oncol 30(36):4456–4457. doi: 10.1200/JCO.2012.45.5402

2. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359(9323):2065–2071. doi: 10.1016/S0140-6736(02)08938-9

3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341(8852):1051–1054

4. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, Lopez A, Lahuerta JJ, Carreras E, Garcia-Conde J, Garcia-Larana J, Cabrera R, Jarque I, Carrera D, Garcia-Ruiz JC, Pascual MJ, Rifon J, Moraleda JM, Perez-Equiza K, Albo C, Diaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marin J, Mateos MV, Fernandez-Ranada JM, Sierra J, Conde E (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 16(4):625–633. doi: 10.1093/annonc/mdi119

5. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12(10):1065–1072. doi: 10.1016/j.bbmt.2006.06.006

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma;JAMA Oncology;2023-05-01

2. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma;Cancer Medicine;2023-04-20

3. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and ‘bridge’ to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma;Leukemia & Lymphoma;2023-01-11

4. 18F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma;Clinical Imaging;2022-12

5. Smart salvage treatment for Hodgkin lymphoma;Blood;2022-06-23